Cellectis S.A. (NASDAQ:CLLS) Receives $7.00 Average Price Target from Brokerages

Shares of Cellectis S.A. (NASDAQ:CLLS) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $7.00.

A number of equities research analysts have issued reports on CLLS shares. Citizens Jmp reissued a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a report on Tuesday, April 14th. Barclays started coverage on shares of Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th.

Cellectis Price Performance

CLLS stock opened at $2.83 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52. Cellectis has a 52 week low of $1.41 and a 52 week high of $5.48. The firm’s fifty day moving average is $3.53 and its 200 day moving average is $3.82. The firm has a market cap of $283.96 million, a P/E ratio of -4.22 and a beta of 2.86.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.04 million.

Institutional Investors Weigh In On Cellectis

Large investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC bought a new stake in Cellectis in the 4th quarter worth $34,000. Lido Advisors LLC bought a new stake in Cellectis in the 1st quarter worth $32,000. Virtu Financial LLC bought a new stake in Cellectis in the 3rd quarter worth $72,000. Acadian Asset Management LLC grew its holdings in Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 26,461 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.